Intuitive Surgical’s $380 Million Share Buyback Fails to Halt the Slide as Guidance Stays Stubbornly Put

Intuitive Surgical beats Q2 estimates but stock plunges 13% after maintaining procedure growth forecast, citing ACA subsidy phase-out and healthcare market recalibration.

The numbers were stellar. The reaction was anything but. Intuitive Surgical delivered a second-quarter performance that beat analyst estimates on both revenue and earnings, yet the stock has been punished with a ferocity that leaves the robotics pioneer trading just a whisker above its 52-week low. The disconnect isn’t about what the company achieved — it’s about what it refused to promise.

Revenue surged 19 percent to $2.89 billion in the three months ended June 30, while adjusted earnings per share of $2.80 comfortably topped the $2.51 consensus. GAAP net income climbed 24 percent to $818 million. But when the da Vinci maker stuck to its full-year procedure growth forecast of 13.5 to 15.5 percent — despite already clocking 15 percent growth in the quarter — investors bolted. The stock plunged as much as 13 percent on July 17 and has struggled to recover, closing Tuesday at €306.95, barely 2.45 percent above the €299.60 52-week low touched on July 20.

The ACA Hangover That Won’t Quit

Chief Financial Officer Jamie Samath offered a sobering explanation in the earnings release. The phase-out of enhanced subsidies under the Affordable Care Act has had a “moderate” negative impact on U.S. procedure volumes. That single line has ignited a debate among analysts and investors about whether the post-pandemic demand surge for robotic surgeries is losing steam as government support fades.

CEO Dave Rosa echoed the caution, noting the subsidy expiration created headwinds that the company felt compelled to acknowledge. The market, however, had been hoping for an upgrade to the guidance range after the strong quarterly showing. Instead, it got a reminder that the U.S. healthcare market is recalibrating — and Intuitive Surgical is not immune.

Da Vinci 5 Adoption Accelerates

While the stock languishes, the operating story remains compelling. The company installed 468 new da Vinci systems in the quarter, with more than half — 246 units — already the next-generation da Vinci 5 platform. That compares with just 180 da Vinci 5 installations in the year-ago period, signaling rapid adoption among hospitals and surgical centers.

The global installed base of da Vinci systems has swelled to 11,710, up 12 percent year over year. The Ion endoluminal system for lung biopsies is gaining even faster, with procedures jumping 36 percent and the installed base reaching 1,096 units. A one-time benefit of $28 million after tax from tariff refunds added a further tailwind to the bottom line.

Cost-Cutting and Capital Moves

Beneath the surface, Intuitive Surgical is preparing for a more price-sensitive environment. The company announced a cost-reduction program set to take effect in the first half of 2027, including longer instrument lifecycles and a push toward leasing models — already at 54 percent of placements — along with the lower-cost XiR system to lower the entry barrier for cash-strapped hospitals.

On July 22, the company filed a shelf registration for $1.77 billion related to an employee stock purchase plan. While the filing provides flexibility for future equity grants, it also introduces a potential dilution risk for existing shareholders — a concern that has weighed on sentiment.

Buyback Signals Management Conviction

Amid the turmoil, management has put its money where its mouth is. Intuitive Surgical repurchased $380 million of its own shares during the second quarter, a signal that the board sees value at current levels. With roughly $8.6 billion in cash and investments, the company has ample firepower to continue buying.

The stock’s technical picture, however, remains bleak. Down 36.67 percent year to date, the shares are trading 40 percent below the January record high of €516.50. The relative strength index sits at 33.1 — deep in oversold territory — suggesting a bounce could be due, though history offers no guarantees. The stock is currently 13.22 percent below its 50-day moving average of €356.99, underscoring the persistent downward momentum.

Valuation Debate Intensifies

Analysts remain split on where the stock goes from here. One Motley Fool-cited price target of roughly $497.87 implies about 30 percent upside from recent levels, while Simply Wall St estimates the stock is 15.7 percent undervalued. Trefis calculates that Intuitive Surgical would need to deliver annual revenue growth of 14.1 percent over four years to justify its current price-to-earnings ratio of 42.1 — a target that looks achievable given the company’s 21 percent growth rate and three-year average of 18.1 percent.

Risks, however, are mounting. Trefis flagged potential deceleration in U.S. procedures and pressure from GLP-1 weight-loss drugs on bariatric surgery, a key market for da Vinci systems. The competitive landscape also offers a cautionary tale: smaller rival Vicarious Surgical voted on July 21 to liquidate after burning through roughly $300 million without bringing a viable product to market — a reminder of just how capital-intensive the surgical robotics business remains.

What Comes Next

The third-quarter results will be pivotal. If procedure growth accelerates despite the ACA headwind, the current sell-off will look overdone. If the guidance proves prescient and growth slows, the stock could face another leg down. For now, Intuitive Surgical is caught between a stellar operational story and a market that wants more certainty — a tension that $380 million in buybacks has yet to resolve.